4-Week Randomized Multicenter DB, Placebo- and Active-Controlled, Parallel-Group, Forced-Titration Phase 2B Study of Efficacy and Safety With CG5503 Prolonged Release (PR) to 233 mg BID and Oxycodone PR to 20 mg BID vs Placebo in Subjects With Moderate to Severe Chronic Pain of Knee Osteoarthritis.

Trial Profile

4-Week Randomized Multicenter DB, Placebo- and Active-Controlled, Parallel-Group, Forced-Titration Phase 2B Study of Efficacy and Safety With CG5503 Prolonged Release (PR) to 233 mg BID and Oxycodone PR to 20 mg BID vs Placebo in Subjects With Moderate to Severe Chronic Pain of Knee Osteoarthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2010

At a glance

  • Drugs Oxycodone; Tapentadol
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 05 Feb 2009 Planned number of patients changed from 568 to 670 as reported by ClinicalTrials.gov.
    • 18 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top